Search Results for: Ritonavir

March 23, 2025March 23, 2025

Evaluation of pharmacist-prescribed nirmatrelvir/ritonavir for patients with COVID-19.

Publication date: Mar 22, 2025 In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed ... Read more

March 20, 2025March 20, 2025

Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma.

Coronavirus Literature

Publication date: Feb 01, 2025 A 58-year-old male developed three coronavirus disease 2019 (COVID-19) relapses within three months after rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy against relapsed follicular ... Read more

March 20, 2025March 20, 2025

Successful 30-Day Nirmatrelvir/Ritonavir Treatment of a Patient Who Developed Multi-relapsed COVID-19 After Receiving R-CHOP Against Follicular Lymphoma.

Coronavirus Literature

March 13, 2025March 13, 2025

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.

Coronavirus Literature

Publication date: Mar 01, 2025 Open Access PDF Concepts Keywords Nirmatrelvir Adult Outpatients Antiviral Agents Severe Antiviral Agents Spanish Cost-Benefit Analysis cost‐effectiveness COVID-19 COVID-19 Drug Treatment COVID‐19 Disease Progression Drug ... Read more

March 13, 2025March 13, 2025

Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain.

Coronavirus Literature

March 6, 2025March 6, 2025

Association between nirmatrelvir/ritonavir treatment and antibiotic prescribing in the outpatient setting among patients with COVID-19.

Coronavirus Literature

Publication date: Mar 05, 2025 Coronavirus disease 2019 (COVID-19) has complicated the management of acute respiratory infections and impacted antibiotic use. We assessed the relationship between nirmatrelvir/ritonavir (NMV/r) receipt and ... Read more

March 6, 2025March 6, 2025

Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild-to-moderate COVID-19: A retrospective study.

Coronavirus Literature

Publication date: Mar 03, 2025 Patients with haematological malignancies (HMs) are highly vulnerable to COVID-19 due to their immunocompromised status, which leads to prolonged viral clearance and severe outcomes. Nirmatrelvir/ritonavir ... Read more

March 6, 2025March 6, 2025

Effectiveness of nirmatrelvir/ritonavir in hospitalized haematological malignancy patients with mild-to-moderate COVID-19: A retrospective study.

Coronavirus Literature

March 2, 2025March 2, 2025

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study.

Coronavirus Literature

Publication date: Feb 28, 2025 Few studies evaluated the effectiveness of COVID-19 antivirals specifically in the asthma population This study assessed short- and long-term effects of nirmatrelvir/ritonavir versus molnupiravir in ... Read more

March 1, 2025March 1, 2025

Effects of nirmatrelvir/ritonavir (Paxlovid) on the nervous system: analysis on adverse events released by FDA.

Coronavirus Literature

Publication date: Feb 27, 2025 Nirmatrelvir/ritonavir, commonly known as Paxlovid, is one of the main drugs used to treat COVID-19. Neurological disorders are among the adverse drug reactions (ADRs) linked ... Read more